Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AstraZeneca to Provide UK Academics with Access to Compound Library

Published: Friday, December 09, 2011
Last Updated: Friday, December 09, 2011
Bookmark and Share
Their groundbreaking new collaboration with the Medical Research Council (MRC) will see the company providing the UK academic sector with access to 22 drugs.

Under the terms of the agreement, British medical researchers will be able to access the drugs developed by AstraZeneca in order to conduct studies into disease mechanisms, thus paving the way for innovative new therapies.

As part of this partnership, the MRC will be inviting research proposals from the academic community to utilise these compounds in new areas, with funding of up to ten million pounds allocated to support the most promising projects.

Proposals that duplicate or overlap with AstraZeneca's own developmental programmes will not be eligible for funding, but the company is open to the idea of working with these researchers directly.

David Brennan, AstraZeneca's chief executive officer, said: "Innovative collaborations are playing a crucial role in finding ways to unlock the potential of new treatments."

Last month, the company committed a new cash injection to its venture capital arm MedImmune Ventures, in order to fund research in new therapy areas and regions.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca, Lilly to Study Immuno-Oncology Combination
This collaboration sets out to assess the efficacy of a combinatorial treatment in patients with advanced solid state tumors.
Monday, June 01, 2015
AstraZeneca and Harvard Stem Cell Institute Collaborate
Collaboration will develop the use of stem cells for diabetes research.
Wednesday, March 25, 2015
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca and the Broad Institute Collaborate
Partnership to advance discovery of antibacterial and antiviral agents.
Tuesday, September 11, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!